SLS (SELLAS Life Sciences) סך נכסי החברה
The daily price chart for the total asset volume of SELLAS Life Sciences (SLS), which stands at 88.83, allows for an assessment of the resource base required to complete the GPS vaccine trials against leukemia. SELLAS Life Sciences (SLS) targets the oncology patient market, relying on payments from pharma behemoths and insurance providers. Since there are no stable sales, the business's financial stability relies exclusively on external investments and capital inflows.
%20-%20%D7%A0%D7%9B%D7%A1%D7%99%D7%9D%20%D7%9E%D7%A6%D7%A8%D7%A4%D7%99%D7%99%D7%9D%20%D7%A9%D7%9C%20%D7%94%D7%97%D7%91%D7%A8%D7%94&width=1200&height=400&colorIndex=0&v=mvq8bmkb.8d-7aozthc&start=20220704&end=20261027&filename=GURU_Markets_-_SLS_-_SELLAS-Life-Sciences_-_Aggregate-Company-Assets "sellaslifesciences.com (SLS): סך נכסי הפעילות העסקית מ-04.07.2022 עד 27.10.2026 | 👁️GURU.Markets👁️")
פילוחי נתונים אנליטיים מרוכזים עבור sellaslifesciences.com (SLS)
SELLAS Life Sciences focuses on developing cutting-edge drugs for the treatment of myeloid leukemia, targeting highly specialized clinics. Total assets here are reverse-calculated via return on assets (ROA), allowing for an objective comparison of the company's resource base against its competitors. This metric serves as an indicator of financial stability during the conduct of costly clinical trials. The trend in the company's asset figures helps detect imbalances between capital growth and real liquidity in a timely manner.